ARGX - argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline - Click For R
ARGX - argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.